However, to the best of our knowledge, no antibodies have been reported that target the aberrant amyloidogenic peptide AGelD187N in Finnish gelsolin amyloidosis, although the pathophysiology of this systemic hereditary disease is straightforward and well understood, unlike in other protein misfolding diseases. This evidence concerns the gene GSN and amyloidosis.